Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 19.
doi: 10.1007/s00210-024-03346-7. Online ahead of print.

Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer

Jing Sun  1 , Yan Tian  1 , Changqing Yang  2
Affiliations
Review

Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer

Jing Sun et al. Naunyn Schmiedebergs Arch Pharmacol. .

Abstract

The T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), a newly discovered checkpoint, is characterized by its elevated expression on CD4 + T cells, CD8 + T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). Research to date has been shown that TIGIT has been linked to exhaustion of NK cell both and T cells in numerous cancers. CD155, being the specific ligand of TIGIT in humans, emerges as a key target for immunotherapy owing to its crucial interaction with TIGIT. Furthermore, numerous studies have demonstrated that the combination of TIGIT with other immune checkpoint inhibitors (ICIs) and/or traditional treatments elicits a potent antitumor response in colorectal cancer (CRC). This review provides an overview of the structure, function, and signaling pathways associated with TIGIT across multiple immune system cell types. Additionally, focusing on the role of TIGIT in the progression of CRC, this study reviewed various studies exploring TIGIT-based immunotherapy in CRC.

Keywords: Cancer immunotherapy; Clinical trial; Colorectal cancer; Immune checkpoint; TIGIT.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Annese T, Tamma R, Ribatti D (2022) Update in TIGIT immune-checkpoint role in cancer. Front Oncol 12:871085 - PubMed - DOI
    1. Bevelacqua V, Bevelacqua Y, Candido S, Skarmoutsou E, Amoroso A, Guarneri C et al (2012) Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma. Oncotarget 3(8):882–892 - PubMed - DOI
    1. Bi J, Tian Z (2019) NK Cell dysfunction and checkpoint immunotherapy. Front Immunol 10:1999 - PubMed - DOI
    1. Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A et al (2009) Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 10(1):29–37 - PubMed - DOI
    1. Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C, Li W et al (2019) Patterns of TIGIT expression in lymphatic tissue, inflammation, and cancer. Dis Markers 2019:5160565 - PubMed - DOI

LinkOut - more resources